First, the good stuff. Here's my portfolio ...
Consumer Discretionary: MCD, NKE, SBUX, TGT
Consumer Staples: COST, GIS, KHC, KO, MO, PEP, PG, PM, RAI, WBA
Energy: CVX, KMI, XOM
Health: ABBV, AMGN, GILD, JNJ, MCK
Industrial: BA, DE, EMR, LMT, MMM
REITs: HCN, NNN, O, OHI, VTR
Technology: AAPL, MSFT, QCOM
Telecom: BCE, T, TU, VZ
Utilities: AVA, D, SCG, SO, WEC
ALSO: small stakes in 23 additional companies held in the Dividend Growth 50 portfolio (http://seekingalpha.com/article/2764265-its-new-its-nifty-its-the-dividend-growth-50): ADP, AFL, BAX, BDX, CAT, CL, CLX, COP, GE, GPC, HCP, HSY, IBM, KMB, MKC, NEE, SHPG, SJM, UTX, V, WFC, WMT.
Now, a little about me:
I am a 50-something former sportswriter who was sent on a permanent vacation during the Great Recession. That sucked, but my story is not a sad one. Unlike many folks who lost their jobs, I am not in financial distress, I am not depressed and I am not bored.
My wife is a pediatric nurse with a bullet-proof job and decent benefits. So after supporting her and our two kids (now grown) for most of three decades, the least she can do is support my semi-retired keister!
Because of Roberta's job situation, because we have zero debt (not even mortgage debt), because we no longer have any dependents and because we have been pretty diligent savers over the years, we are comfortable (though nowhere near rich).
Although we hold some funds, bonds and cash, my investing philosophy leans heavily toward Dividend Growth Investing. By early next decade, we want to live entirely off of our income stream, Social Security and pension payments - and therefore will not have to spend down the principal one iota. To accomplish this, we invest mostly in blue-chip companies with long track records of growing dividends. As of mid-2016, we are well ahead of pace to reach our goal.
When not researching investments and writing for Seeking Alpha and other Web sites, I coach middle-school girls basketball at Metrolina Regional Scholars Academy, the top charter school in the Charlotte metro area; in March 2016, we won the first conference championship in school history! I also umpire youth baseball and referee youth basketball.
My wife and I dote on our 5-year-old pup, Simmie, and keep up on the doings of our now-grown kids, Katie and Ben. And we love to cheer on the basketball team of our alma mater, Marquette University, where we both majored in Journalism. Go Warriors! Also big fans of the Carolina Panthers.
I still occasionally post to the blog I initiated in 2007 -- lots of sports stuff, some politics, some personal junk -- at www.TheBaldestTruth.com.
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
Data Center Knowledge - Contributor: writing about data centers REITs -- a new and growing asset class -- attempting to bridge the gap between technology & traditional REIT investors.
Researching and writing at the corner of Main St. & Wall St. where real estate often intersects with trends in: technology, ecommerce, office/industrial, healthcare, cloud computing, energy infrastructure & green initiatives.
Recently covered breaking news and actionable ideas REIT ideas for Benzinga "REIT Beat," now Contributor/Sr. REIT Expert. Select articles featured on Investopedia.com, Seeking Alpha, and published on Yahoo! Finance, Google, MSN, Finviz and many other financial portals. Recent Select Freelance contributor for Motley Fool, writing about REITs and real estate topics for the Financial Bureau.
I have over 25 years of experience as a: developer of institutional quality office and industrial facilities, general contractor, homebuilder, managing general partner for private limited partnerships, and have performed consulting and transactional real estate services for others, including entitlements for planned commercial/office/industrial developments.
Past job experience included: V.P. of Energy Services for a Florida based Mechanical Contracting company, which subsequently was acquired by EMCOR (NYSE: EME). Responsibilities included development and "financial engineering" of projects to reduce energy consumption and total cost of ownership solutions, partnered with the two major Florida electric utilities, and private companies, (including Enron Energy Services!).
Education: UCLA - BA Economics, including graduate coursework in Real Estate Finance.
Masters Degree from St. Thomas University - Miami, FL
My name is Tarun Chandra, and I've been an Analyst on both Buyside and Sellside. In addition, I've worked in Corporate Strategy and Finance roles for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for individual investors. Prudent Biotech portfolio is a quantitative-driven systematic investing product. More can be learnt about our Biotechnology portfolio at the website PrudentBiotech.com. You may also visit our website GraycellAdvisors.com for a view of our approach and all products.
I used to run a limited partnership, boutique hedge fund in the 90s. Retired in 2000 and moved from New York City to Toronto, Canada, got married, raised a family and basically settled down. After a few years in Toronto, my wife got tired of the city’s 8 months of cold weather and insisted that we move to a city where there are 8 months of warm and balmy weather. So we settled on San Diego, CA and moved here in 2005 and now call this lovely city with the most perfect weather, home. After moving to Sun Diego, I decided to come out of retirement and start an Internet company that helps non-profits, especially school PTAs, raise money. After a somewhat long development period, my start-up, called donornation.org, went live this month (December 2012)! The response so far has been quite encouraging and I intend to take the company from its current, local San Diego focus, to nationwide, hopefully in the next 2 years. Feel free to check it out and let me know what you think…any feedback and suggestions to help improve the site is always welcome. Being that my day job is running a tech start-up, I don’t have the time to be an active trader…However, being an avid market watcher and investor, I started this blog to maintain a public record of my views on the economy, the markets and my stock picks. My space here has given me the opportunity to share my analysis, good, bad and the ugly, with everyone. It has also allowed me to keep a running scorecard on how effective my investment ideas have been. About a year ago, just after my Options2Wealth blog's public portfolio recorded 10,000%+ return in less than 6 months, I received an offer to write a book based on my blog's accomplishment by one of the most respected literary agents in the United States. This was a totally unintended and unexpected result of my original motivation which was to simply help demystify derivatives (options) and show how just about anyone, armed with the ability to read stock charts, can take advantage of the most powerful wealth building tool legally available to us all. Based on the fact that some of my readers were able to mimic my moves and achieve returns of as much as 4,000%+ tells me that my blog has succeeded in its raison d'être. Finally, I shall be remiss if I did not acknowledge the many public and private comments / messages that I have received, and continue to receive, from my readers here. I want to take this opportunity to let you know that I'm extremely grateful, and humbled, to all those who have taken the time to share your comments, kind thoughts and warm wishes with me...Should you not receive a reply, please do not take my lack of responsiveness as a sign of hubris...Due to my various interests and activities and the fact that I spend a considerable amount of time traveling, my free time is extremely limited and if I have not responded to your message, please accept my sincere apologies... Best of Luck to All! karim pirani
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
Steven Hansen is an international business and industrial consultant specializing in turning around troubled business units; consults to governments to optimize process flows; and provides economic indicator analysis based on unadjusted data and process limitations.
Dr. Chris Martenson is an independent economist and author of a popular website, ChrisMartenson.com. His Crash Course video series explores the intertwining significance of the “three E’s”—the economy, energy, and environment and offers articulate, dynamic insight into the workings of our monetary system.
Chris earned a PhD in neurotoxicology from Duke University, and an MBA from Cornell University. His background as an educator helps him animate complex material with wisdom and humor. A fellow of the Post Carbon Institute, Chris’s work has appeared on PBS and been cited by the Washington Post. He is a contributor to the Huffington Post and FinancialSense.com.
Chris is an accomplished presenter who has offered the Crash Course seminar all over the United States. The online course has been translated into several languages, and been viewed nearly a million times. His website offers ongoing commentary and rigorously factual analysis into financial and energy-related issues and events as they unfold.
Brett N. Steenbarger, Ph.D. is Clinical Associate Professor of Psychiatry and Behavioral Sciences at SUNY Upstate Medical University in Syracuse, NY. He is also a trader in the equities markets and works with traders in proprietary, hedge fund, and investment bank settings.
Dr. Steenbarger has authored The Psychology of Trading (Wiley, 2003) and Enhancing Trader Performance (Wiley, 2006), as well as over 50 peer-reviewed professional publications in psychology and psychiatry. He maintains an archive of free articles and research at www.brettsteenbarger.com and writes a daily blog on market psychology at www.traderfeed.blogspot.com.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
Bill Gunderson @billgunderson is the CEO and Chief Market Strategist of Gunderson Capital Managment in San Diego, CA.
He is also a professional money manager, former research analyst, author of Best Stocks Now, and developer of the Best Stocks Now smartphone app.
He offers four free weeks to his weekly Best Stocks Now to Seeking Alpha readers at gundersoncapital.com
He also hosts a daily stock market radio show that is syndicated nationwide on the Salem Broadcast Network.
Bill has appeared on the Fox Business Channel and on Bloomberg Radio numerous times .His articles have been published in Barron's, Forbes, TheStreet.com and numerous other publications.
He can be reached at email@example.com or by calling (855)611-BEST.
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
I am currently in my 4th year of Bachelor of Engineering in the Engineering Physics discipline with specializations in Nanotechnology and Micro-Electrical-Mechanical Systems. It’s no secret the discipline and specialization I have pursued is not as popular as the Mechanical and Electrical Discipline, and why would it be? Who would want to spend several thousands of hours of reading literature, running simulations and performing labs on topics as new as tandem organic photovoltaic architectures, CMOS fabrication process, quantum mechanical processes in modern devices, while still having to be virtually as competent as our counterparts in electrical, software and computer? Well the answer is approximately 40 of the 1500 or so engineers graduating next year. One thing that all these students have in common, including myself, besides the obvious sleep deprivation and copious caffeine consumption is the tenacity to not sleep till anything and everything that comes our way has been mastered. With that being said, I approach my research with the same rigor and thoroughness I have become accustomed to over the past four years. In conclusion, I aim to bring my best independent thought to the readers as I would expect being an investor myself.
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
Accuvest Global Advisors is located in California and serves as an investment advisor to high-net-worth families, foundations, endowments and pension plans, as well as a sub-advisor to financial institutions. Accuvest manages global equity, global asset allocation (CST®), global tactical and liquid alternatives portfolios for a diverse, global client base. Accuvest believes that a global portfolio is a better portfolio.
Contributors for the Accuvest Global Advisors Seeking Alpha profile include David Garff (President and CIO), Brad Jensen (Managing Director), David Allen (Senior Portfolio Manager), and James Calhoun (Portfolio Manager/Research Analyst).
EXP is a graduate from The University of Wall Street and serves as the CEO / Chief Stock Strategist at EXPstocktrader.com research firm.
With over 30 years of trading the market, EXP is an experienced investor using a fundamental and technical approach as a market analyst, chartist, visual analyst, as well as, a trader, author, coach, and serial entrepreneur. Extremely dedicated by investing countless hours investigating, analyzing, then writing about unique stock opportunities, as well as, coaching existing followers worldwide. EXP delivers "Real Facts" to Seeking Alpha and Twitter followers on monthly stock selections. Not all of the research found in the EXPstocktrader Monthly Newsletter is openly published online so EXP's members get updates first. Note: Most stocks covered have a unique niche or value proposition.
The Goal is to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. From the EXPstocktrader.com website you will find an offering for a newsletter that gives interested followers several trading ideas and stock lessons on a monthly basis. SA followers only see a very small part of EXP's published research.
This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them.
EXP resides in the USA, and is thankful to followers worldwide.
You can also follow EXPstocktrader on:
Twitter --- @EXPstocktrader
Website --- http://www.EXPstocktrader.com
Email --- firstname.lastname@example.org
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader.com and SA are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
David Moenning is Chief Investment Officer at Sowell Management Services, a registered investment advisor with more than $500 million under management. Sowell emphasizes an MPD (Modern Portfolio Diversification) approach to portfolio design which diversifies client holdings not only across asset classes but also by strategy, manager, and investment methodology. Dave began his investment career in 1980 and has been an independent money manager since 1987. Thus, Dave has been live on the firing line and investing for a living for nearly 30 years.
Bioassociate is an Israeli company established in 2008 and operating in the life science arena. Bioassociate provides expertise-based consulting, research and analysis services to international life science companies and investment entities (investment banks, private and institutional investors). Visit our website at www.bioassociate.com.
Currently going for MBA in finance. Personally invest mainly in biotechs and all opinions are my own. Follow me @KeithStokes14 on twitter (I discuss trades and companies, mainly small-cap biotechs).
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
Marty Chilberg is a seasoned financial professional with over 30 years of executive leadership, board, consulting and advisory experience. He began his career as a certified public accountant (CPA). He moved to Silicon Valley in 1981 to begin his career in the software industry, working for Atari, Daisy Systems, Symantec and Visio. He took Symantec and Visio through their initial public offerings as their Chief Accounting Officer and Chief Financial Officer, respectively. From 1997 to present, his time has been spent on consulting and advisory services while joining several corporate and community boards. For the past several years the majority of his activities have been focused on investing.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
Post-graduate student in chemical + bioengineering, get my kicks by learning about things that interest me! Looking to use my expertise and knowledge to better communicate biotech trade ideas to the average investor.